Consensus EPS · Q2 2026
$2.91
Consensus revenue · Q2 2026
$1.7B
Analysts
9
Last reported
Jul 22, 2026
Analyst consensus
Based on estimates from 9 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $1.7B | $1.7B | $1.7B |
| EPS | $2.84 | $2.91 | $2.94 |
| EBITDA | $1.5B | $1.5B | $1.6B |
| EBIT | $1.5B | $1.5B | $1.5B |
| Net income | $1B | $1.1B | $1.1B |
- Revenue$1.7B
- EPS$2.91
- EBITDA$1.5B
- EBIT$1.5B
- Net income$1.1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $1.7B | $1.7B | +1.4% | $2.99 | $2.91 | +2.9% |
| Q1 2026 | $1.9B | $1.9B | +0.3% | $3.36 | $3.34 | +0.5% |
| Q4 2025 | $1.7B | $1.6B | +0.2% | $2.77 | $2.75 | +0.7% |
- Q2 2026+1.4%+2.9%
- Q1 2026+0.3%+0.5%
- Q4 2025+0.2%+0.7%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
No community consensus
No TickerLeague members predicted CME Group (CME) Q2 2026 before it reported.
Analyst price target
Based on price targets from 3 analysts.
- Low
- $260.00
- Consensus
- $303.33
- Median
- $309.00
- High
- $324.00
- Current
- $249.24
- Upside
- +21.7%
Upside calculated vs most recent trading price of $249.24.
Analyst ratings
Consensus: Hold — based on 37 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| Jul 10, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 9, 2026 | Barclays | maintain | Equal Weight | Equal Weight |
| Jul 8, 2026 | TD Cowen | maintain | Buy | Buy |
| Jul 6, 2026 | UBS | maintain | Neutral | Neutral |
| Jul 2, 2026 | Raymond James | maintain | Outperform | Outperform |
| Jun 22, 2026 | TD Cowen | maintain | Buy | Buy |
| Jun 18, 2026 | Keefe, Bruyette & Woods | upgrade | Market Perform | Outperform |
| Jun 11, 2026 | Rothschild & Co | upgrade | Neutral | Buy |
| Jun 5, 2026 | Erste Group | downgrade | Buy | Hold |
- Jul 15, 2026Piper SandlerOverweight
- Jul 10, 2026Morgan StanleyOverweight
- Jul 9, 2026BarclaysEqual Weight
- Jul 8, 2026TD CowenBuy
- Jul 6, 2026UBSNeutral
- Jul 2, 2026Raymond JamesOutperform
- Jun 22, 2026TD CowenBuy
- Jun 18, 2026Keefe, Bruyette & WoodsOutperform
- Jun 11, 2026Rothschild & CoBuy
- Jun 5, 2026Erste GroupHold
Frequently asked questions
CME Group (CME) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.78% TTM
- Dividend Profile4.51% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History1 split
How this company returns cash to shareholders — buybacks, dividends, and stock splits.